After an excellent Q1 (+13%) – driven by COVID-19-induced forward buying, sales growth tanked in Q2 (-1%). There was moderation across the board, although it was severe in ophthalmology (-18%) and Sandoz (-9%). Even the lynchpin oncology franchise’s growth was reduced to 1%. While there are signs of recovery, complete normalisation may take a few quarters, especially considering the risk of a second-wave of infections. Although, given Novartis’ relatively-lower sales and pro
22 Jul 2020
Weak Q2 as Q1’s extraordinary gains retreated
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Weak Q2 as Q1’s extraordinary gains retreated
Novartis AG (0QLR:LON) | 0 0 0.7% | Mkt Cap: 208,186m
- Published:
22 Jul 2020 -
Author:
Surbhit Gupta -
Pages:
6
After an excellent Q1 (+13%) – driven by COVID-19-induced forward buying, sales growth tanked in Q2 (-1%). There was moderation across the board, although it was severe in ophthalmology (-18%) and Sandoz (-9%). Even the lynchpin oncology franchise’s growth was reduced to 1%. While there are signs of recovery, complete normalisation may take a few quarters, especially considering the risk of a second-wave of infections. Although, given Novartis’ relatively-lower sales and pro